Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "House Dust Mite Allergy - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in House Dust Mite Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
House Dust Mite Allergy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the House Dust Mite Allergy pipeline landscape is provided which includes the disease overview and House Dust Mite Allergy treatment guidelines. The assessment part of the report embraces, in depth House Dust Mite Allergy commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, House Dust Mite Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for House Dust Mite Allergy. In the coming years, the House Dust Mite Allergy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence House Dust Mite Allergy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. A detailed portfolio of major pharma players who are involved in fueling the House Dust Mite Allergy treatment market. Several potential therapies for House Dust Mite Allergy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the House Dust Mite Allergy market size in the coming years.
This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of House Dust Mite Allergy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
House Dust Mite Allergy Emerging Drugs Chapters
This segment of the House Dust Mite Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
House Dust Mite Allergy Emerging Drugs
Tregalizumab: T-Balance Therapeutics Tregalizumab selectively activates the immunomodulatory subpopulation of T cells called regulatory T cells or Tregs. Tregs are essential for maintaining peripheral immune tolerance; they suppress autoreactive T cells (i.e. cells targeted against the body's own structures) and thereby prevent the excessive activation of T lymphocytes seen in autoimmune and inflammatory diseases. Tregalizumab acts early in the inflammatory cascade, providing the opportunity for a novel therapeutic approach aimed at the prevention and treatment of inflammatory conditions.
FP-025: Foresee PharmaceuticalsFP-025 is a highly selective (non-hydroxamate), oral non-competitive small molecule inhibitors of Matrix Metalloproteinase-12/Macrophage elastase (MMP-12), an enzyme that acts as a key mediator of matrix degradation and remodeling in both normal development and maintenance. FP-025 is well tolerated in healthy human volunteers and allergic asthmatic patients upon single and repeat dosing, and exhibits good single and multiple dose oral pharmacokinetics.
Key Questions
- How many companies are developing House Dust Mite Allergy drugs?
- How many House Dust Mite Allergy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of House Dust Mite Allergy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the House Dust Mite Allergy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for House Dust Mite Allergy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- T-Balance Therapeutics
- Worg Pharmaceuticals
- Advagene Biopharma Co., Ltd.
- Immunotek SL
- Tolerogenics S.a.r.l.
- Foresee Pharmaceuticals
Key Products
- Tregalizumab
- WP1049
- Airway Allergy Immunotherapy
- MM09-MG01
- FP-025
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
House Dust Mite Allergy Report Insights
- House Dust Mite Allergy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
House Dust Mite Allergy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/3thkfu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
